中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

4 records (took 0.01 seconds)

    TOLL-LIKE RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF
    2.
    发明申请
    TOLL-LIKE RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF 失效
    TOLL-LIKE受体激动剂和拮抗剂及其使用方法

    公开(公告)号：US20080167242A1

    公开(公告)日：2008-07-10

    申请号：US11963610

    申请日：2007-12-21

    Applicant: Richard D. Ye ,  Ni Cheng ,  Rong L. He

    Inventor： Richard D. Ye ,  Ni Cheng ,  Rong L. He

    IPC: A61K38/16 ,  A61K31/7088 ,  C12Q1/68 ,  C12N5/08 ,  A61P37/04

    CPC classification number: A61K39/39 ,  A61K31/7088 ,  A61K38/1716 ,  A61K2039/55516

    Abstract: The present disclosure relates to compositions and methods of modulating inflammatory and immune responses through binding of SAA to TLR2 in a subject (e.g., human, non-human primate, rodent, etc.), and compositions and methods for screening TLR2 agonists and antagonists. In the studies described herein, a potential role of SAA in neutrophilia was investigated and the results demonstrated that SAA is a potent inducer for macrophage secretion of G-CSF, which leads to neutrophilia in mice. Using G-CSF−/− and TLR2−/− mice, it was found that the SAA-induced neutrophilia is dependent on TLR2-mediated production of G-CSF. Based on direct binding assay and gain-of-function studies in TLR2-transfected cells, SAA was identified as a novel ligand for TLR2 and a link between increased SAA concentration and TLR2-mediated inflammatory responses such as neutrophilia was established. Additional embodiments are disclosed.

    Abstract translation: 本公开涉及通过在受试者（例如人，非人灵长类动物，啮齿动物等）中结合SAA与TLR2调节炎症和免疫应答的组合物和方法，以及用于筛选TLR2激动剂和拮抗剂的组合物和方法。 在本文所述的研究中，研究了SAA在嗜中性粒细胞增多中的潜在作用，结果表明SAA是巨噬细胞分泌G-CSF的有效诱导剂，导致小鼠嗜中性粒细胞增多。 使用G-CSF小鼠，发现SAA诱导的嗜中性白细胞增多依赖于TLR2介导的G-CSF产生。 基于TLR2转染细胞的直接结合测定和获得功能研究，SAA被鉴定为TLR2的新配体，并且建立了增加的SAA浓度和TLR2介导的炎症反应如中性粒细胞增多之间的联系。 公开了另外的实施例。

    G protein-coupled receptor with an enlarged extracellular domain
    3.
    发明授权
    G protein-coupled receptor with an enlarged extracellular domain 失效

    公开(公告)号：US06521418B1

    公开(公告)日：2003-02-18

    申请号：US09117440

    申请日：1998-07-28

    Applicant: Richard D. Ye

    Inventor： Richard D. Ye

    IPC: C12N1500

    CPC classification number: C07K14/723 ,  A61K38/00

    Abstract: The invention features a G protein-coupled receptor that has an enlarged extracellular loop between the fourth and fifth transmembrane domains. A nucleic acid encoding the receptor was isolated from a human granulocytic cell library and antibodies generated against the polypeptide revealed expression in a variety of tissues including heart, placenta, and lung. This antibody, or others that specifically bind the G protein-coupled receptor of the invention, can be used in the diagnosis of diseases or conditions that are associated with upregulation of the receptor, as occurs, for example, when hematopoietic cells differentiate. These diseases include inflammatory and neurological diseases, particularly Alzheimer's Disease. The nucleic acids, polypeptides, and antibodies described herein can also be used as therapeutic agents to treat these diseases by inhibiting the expression or activity of the receptor. They can also be used in the treatment of obesity.

    Toll-like receptor agonists and antagonists and methods of use thereof
    4.
    发明授权
    Toll-like receptor agonists and antagonists and methods of use thereof 失效
    Toll样受体激动剂和拮抗剂及其使用方法

    公开(公告)号：US07629135B2

    公开(公告)日：2009-12-08

    申请号：US11963610

    申请日：2007-12-21

    Applicant: Richard D. Ye ,  Ni Cheng ,  Rong L. He

    Inventor： Richard D. Ye ,  Ni Cheng ,  Rong L. He

    IPC: G01N33/53 ,  G01N33/567 ,  C12N5/00 ,  C12N5/02 ,  C12P21/06 ,  C07K14/00 ,  A61K38/29 ,  C07H21/04 ,  C07H21/02

    CPC classification number: A61K39/39 ,  A61K31/7088 ,  A61K38/1716 ,  A61K2039/55516

    Abstract: The present disclosure relates to compositions and methods of modulating inflammatory and immune responses through binding of SAA to TLR2 in a subject (e.g., human, non-human primate, rodent, etc.), and compositions and methods for screening TLR2 agonists and antagonists. In the studies described herein, a potential role of SAA in neutrophilia was investigated and the results demonstrated that SAA is a potent inducer for macrophage secretion of G-CSF, which leads to neutrophilia in mice. Using G-CSF−/− and TLR2−/− mice, it was found that the SAA-induced neutrophilia is dependent on TLR2-mediated production of G-CSF. Based on direct binding assay and gain-of-function studies in TLR2-transfected cells, SAA was identified as a novel ligand for TLR2 and a link between increased SAA concentration and TLR2-mediated inflammatory responses such as neutrophilia was established. Additional embodiments are disclosed.

    Abstract translation: 本公开涉及通过在受试者（例如人，非人灵长类动物，啮齿动物等）中结合SAA与TLR2调节炎症和免疫应答的组合物和方法，以及用于筛选TLR2激动剂和拮抗剂的组合物和方法。 在本文所述的研究中，研究了SAA在嗜中性粒细胞增多中的潜在作用，结果表明SAA是巨噬细胞分泌G-CSF的有效诱导剂，导致小鼠嗜中性粒细胞增多。 使用G-CSF - / - 和TLR2 - / - 小鼠，发现SAA诱导的嗜中性粒细胞增多依赖于TLR2介导的G-CSF产生。 基于TLR2转染细胞的直接结合测定和获得功能研究，SAA被鉴定为TLR2的新配体，并且建立了增加的SAA浓度和TLR2介导的炎症反应如中性粒细胞增多之间的联系。 公开了另外的实施例。

Patent Agency Ranking